|drug1185||Emtricitabine/tenofovir disoproxil Wiki||1.00|
|drug4042||plasma from convalescent patients with COVID-19 Wiki||1.00|
|drug2571||Placebo: Hydroxychloroquine Wiki||1.00|
|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
|D018352||Coronavirus Infections NIH||0.04|
There is one clinical trial.
The aim of this project is to introduce way for treatment of patients with severe COVID-19 disease with respiratory complications.
Description: improvement of general condition of the patients as the ventilator parameters and serum level of ferritin , D dimer, CBC, oxygen level in blood and patient o2 saturationMeasure: improvement of condition Time: three to five days days
Description: change in the liver , kidney function and change in ferritin level with normal D DimerMeasure: change in organs function with PFS and OS Time: 0ne month
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports